OBJECTIVES: The perceptions, motivations, and beliefs of HIV-uninfected women about pre-exposure prophylaxis (PrEP) use during pregnancy can influence its uptake and adherence. This study elicited the views of HIV-uninfected women with personal experience taking PrEP during pregnancy. DESIGN: Qualitative interviews were conducted with HIV-uninfected women who had personal experience taking PrEP while pregnant. METHODS: Semistructured interviews were conducted with 21 HIV-uninfected Kenyan women in HIV-serodiscordant couples enrolled in an open-label PrEP demonstration project who became pregnant while using PrEP and continued PrEP through their pregnancy. Interviews were audio-recorded and transcribed into English. A qualitative descriptive analysis was performed, using a constant comparison approach to identify key themes related to PrEP use in pregnancy. RESULTS: Desire to remain HIV uninfected and have an HIV-free infant were strong motivators influencing continued use of PrEP during pregnancy. Supporting HIV-infected partners and childbearing within an HIV-serodiscordant relationship were also motivators. Women had challenges distinguishing normal pregnancy symptoms from PrEP side effects and were concerned that observed side effects could be signs of danger for the infant related to PrEP exposure. Health care providers were important conduits of knowledge about PrEP, and continuity of PrEP providers throughout pregnancy facilitated adherence. CONCLUSIONS: HIV-uninfected women in HIV-serodiscordant couples were motivated to use PrEP during pregnancy to remain HIV uninfected and to have an HIV-free child but had concerns about side effects. Health care providers will be important for PrEP messaging and adherence support in this unique population.
OBJECTIVES: The perceptions, motivations, and beliefs of HIV-uninfectedwomen about pre-exposure prophylaxis (PrEP) use during pregnancy can influence its uptake and adherence. This study elicited the views of HIV-uninfectedwomen with personal experience taking PrEP during pregnancy. DESIGN: Qualitative interviews were conducted with HIV-uninfectedwomen who had personal experience taking PrEP while pregnant. METHODS: Semistructured interviews were conducted with 21 HIV-uninfected Kenyanwomen in HIV-serodiscordant couples enrolled in an open-label PrEP demonstration project who became pregnant while using PrEP and continued PrEP through their pregnancy. Interviews were audio-recorded and transcribed into English. A qualitative descriptive analysis was performed, using a constant comparison approach to identify key themes related to PrEP use in pregnancy. RESULTS: Desire to remain HIV uninfected and have an HIV-free infant were strong motivators influencing continued use of PrEP during pregnancy. Supporting HIV-infected partners and childbearing within an HIV-serodiscordant relationship were also motivators. Women had challenges distinguishing normal pregnancy symptoms from PrEP side effects and were concerned that observed side effects could be signs of danger for the infant related to PrEP exposure. Health care providers were important conduits of knowledge about PrEP, and continuity of PrEP providers throughout pregnancy facilitated adherence. CONCLUSIONS:HIV-uninfectedwomen in HIV-serodiscordant couples were motivated to use PrEP during pregnancy to remain HIV uninfected and to have an HIV-free child but had concerns about side effects. Health care providers will be important for PrEP messaging and adherence support in this unique population.
Authors: Alexandra Schnack; Eva Rempis; Sarah Decker; Vera Braun; John Rubaihayo; Priscilla Busingye; Nazarius Mbona Tumwesigye; Gundel Harms; Stefanie Theuring Journal: AIDS Patient Care STDS Date: 2016-03 Impact factor: 5.078
Authors: Leigh F Johnson; Kathryn Stinson; Marie-Louise Newell; Ruth M Bland; Harry Moultrie; Mary-Ann Davies; Thomas M Rehle; Rob E Dorrington; Gayle G Sherman Journal: J Acquir Immune Defic Syndr Date: 2012-04-01 Impact factor: 3.731
Authors: Carla E Ransom; Yanling Huo; Kunjal Patel; Gwendolyn B Scott; Heather D Watts; Paige Williams; George K Siberry; Elizabeth G Livingston Journal: J Acquir Immune Defic Syndr Date: 2013-12-01 Impact factor: 3.731
Authors: Frederick Morfaw; Lawrence Mbuagbaw; Lehana Thabane; Clarissa Rodrigues; Ana-Paula Wunderlich; Philip Nana; John Kunda Journal: Syst Rev Date: 2013-01-16
Authors: John Ditekemena; Olivier Koole; Cyril Engmann; Richard Matendo; Antoinette Tshefu; Robert Ryder; Robert Colebunders Journal: Reprod Health Date: 2012-11-21 Impact factor: 3.223
Authors: Jillian Pintye; Alison L Drake; Emily Begnel; John Kinuthia; Felix Abuna; Harison Lagat; Julia Dettinger; Anjuli D Wagner; Harsha Thirumurthy; Kenneth Mugwanya; Jared M Baeten; Grace John-Stewart Journal: AIDS Date: 2019-07-01 Impact factor: 4.177
Authors: Jillian Pintye; John Kinuthia; Felix Abuna; Kenneth Mugwanya; Harison Lagat; Julia C Dettinger; Daniel Odinga; Joseph Sila; Peter L Anderson; Grace John-Stewart; Jared M Baeten Journal: Clin Infect Dis Date: 2020-12-03 Impact factor: 9.079
Authors: Dvora L Joseph Davey; Joseph Daniels; Cindy Beard; Nyiko Mashele; Linda-Gail Bekker; Kathryn Dovel; Jabulani Ncayiyana; Thomas J Coates; Landon Myer Journal: AIDS Care Date: 2020-06-23
Authors: Laia Vazquez; Anthony P Moll; Alexa Kacin; Ntombi Euginia Ndlovu; Sheela V Shenoi Journal: AIDS Patient Care STDS Date: 2019-05 Impact factor: 5.078
Authors: Jillian Pintye; Kristin M Beima-Sofie; Pamela A Makabong'O; Anne Njoroge; Susan Brown Trinidad; Renee A Heffron; Jared M Baeten; Connie Celum; Daniel Matemo; John Kinuthia; Maureen C Kelley; Grace C John-Stewart Journal: AIDS Patient Care STDS Date: 2018-07-23 Impact factor: 5.078
Authors: Jillian Pintye; Dvora L Joseph Davey; Anjuli D Wagner; Grace John-Stewart; Rachel Baggaley; Linda-Gail Bekker; Connie Celum; Benjamin H Chi; Thomas J Coates; Allison K Groves; Jessica E Haberer; Renee Heffron; John Kinuthia; Lynn T Matthews; James A McIntyre; Dhayendre Moodley; Lynne M Mofenson; Nelly Mugo; Andrew Mujugira; Landon Myer; Steven Shoptaw; Lynda Stranix-Chibanda; Jared M Baeten Journal: Lancet HIV Date: 2020-08 Impact factor: 12.767
Authors: Jillian Pintye; John Kinuthia; D Allen Roberts; Anjuli D Wagner; Kenneth Mugwanya; Felix Abuna; Harison Lagat; George Owiti; Carol E Levin; Ruanne V Barnabas; Jared M Baeten; Grace John-Stewart Journal: J Acquir Immune Defic Syndr Date: 2018-12-15 Impact factor: 3.731
Authors: Lauren M Hill; Friday Saidi; Kellie Freeborn; K Rivet Amico; Nora E Rosenberg; Suzanne Maman; Twambilile Phanga; Mercy Tsidya; Sara Chirwa; Chifundo Zimba; Wilbroad Mutale; Benjamin H Chi Journal: PLoS One Date: 2021-06-25 Impact factor: 3.240